Results 211 to 220 of about 108,133 (341)

Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2. [PDF]

Front Mol Biosci
Shao Q, Xiong J, Wu J, Mao J, Hu Q.
europepmc   +1 more source

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

Journal of Diabetes Investigation, EarlyView.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda   +10 more
wiley   +1 more source

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Tamkeen Khan, Stavros Tsipas, Fleetwood Loustalot, Lindsay Zasadzinski, Klodiana Myftari, Alyson B. Goodman, Gregory D. Wozniak   +6 more
doaj   +1 more source

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? [PDF]

Biomolecules
Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, Tentolouris N.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review. [PDF]

Cureus
Ibrahim R, Kambal A, Abdelmajeed MA.
europepmc   +1 more source

Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization. [PDF]

Eur Heart J Cardiovasc Pharmacother
Huang H, Liu J, Lu X, Tan N, Liu Y.
europepmc   +1 more source

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction. [PDF]

J Am Heart Assoc
Ibrahim R, Han W, Wang W, Kau E, Said N, Forst B, Pham HN, Abdelnabi M, Salih M, Ali NB, Farina J, Lester SJ, Lee K, Ayoub C, Arsanjani R.   +14 more
europepmc   +1 more source

Effects of GLP‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

International Journal of Dermatology, EarlyView.
Miranda K. Branyiczky, Megan S. Lowe, Eric McMullen, Jeffrey Donovan, Touraj Khosravi‐Hafshejani   +4 more
wiley   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, EarlyView.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source